EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

ONC201 has exhibited durable tumor regressions in midline high grade glioma patients. G protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) is overexpressed in high grade gliomas, controls several oncogenic mechanisms, and its antagonism causes tumor cell apoptosis. Using bioinformatic and G...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Benjamin Free, R, Cuoco, Caroline, Prabhu, Varun, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Robert Lane, J, Sibley, David, Allen, Joshua
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847112/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.365
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares